ProteinLogic announces successful identification of ImmiPrint diagnostic signatures for several new diseases

CAMBRIDGE, UK (2010-04-27) – ProteinLogic Ltd. (“the Company”), today announced that preliminary ImmiPrint diagnostic signatures have been successfully identified for several new diseases. These encouraging results follow the completion of a range of exploratory tests of different diseases using its proprietary ImmiPrint technology.

ProteinLogic has consequently now demonstrated the utility of its diagnostic technology across several different diseases and disease areas. The sensitivities and specificities make it appropriate for the Company to consider validation of some of the ImmiPrint tests.

The Company believes that the new results constitute a generalised proof of concept for the ImmiPrint diagnostic biomarker discovery platform and demonstrates that it is able to identify preliminary diagnostic signatures for a broad range of different diseases and disease areas. This should help ProteinLogic to extend its validation of ImmiPrint technology as an important new tool in assisting with the rapid identification of blood-based diagnostic biomarker signatures.

Mahesh Shah, ProteinLogic’s CEO, said: “These results are very encouraging and indicate that ImmiPrint signatures could have general diagnostic utility”.

ProteinLogic’s Director of Marketing, Dr Richard Cumming, said: “These extended results indicate the potential utility of the ImmiPrint approach to diagnostic biomarker discovery. The Company looks forward to extending the validation of the ImmiPrint technology that includes cost-effective diagnostic biomarker discovery”.

Notes for Editors:

1. ProteinLogic is a UK registered company based in Cambridge UK whose mission is to deliver diagnostic tests for use in clinical medicine. The technology ‘barcodes’ human diseases using a discrete set of biomarkers present in body fluids. The work was developed by Dr César Milstein and Dr Adrian Woolfson at MRC Laboratory of Molecular Biology in Cambridge and Professor Nick Hales from the Department of Clinical Biochemistry at the University of Cambridge. The technology is based partly on Milstein’s discovery of immune cell surface antigens and his work on monoclonal antibodies, for which he was awarded the Nobel Prize in Medicine and Physiology. The Company was spun out of the Univeristy of Cambridge, Addenbrooke’s NHS Trust and the Medical Research Council Laboratory for Molecular Biology, Cambridge. For further information, visit www.proteinlogic.com.

2. Dr Adrian Woolfson is a molecular biologist and medical doctor. He was the co-founder of ProteinLogic and was formerly a Charles and Katherine Darwin Research Fellow in molecular biology at Darwin College, Cambridge and a Wellcome Trust Clinical Fellow at the MRC Laboratory of Molecular Biology, Cambridge.

3. Dr César Milstein was the co-inventor of the hybridoma technique for the production of monoclonal antibodies for which he was awarded the Nobel Prize in Physiology and Medicine in 1984. He was a Fellow of Darwin College, Cambridge and an Honorary Fellow of Fitzwilliam College, Cambridge. From 1988 to 1995 he was the Deputy Director of the Medical Research Council Laboratory of Molecular Biology, Cambridge.

4. Mr Mahesh Shah was a founding director of Nucare plc, a company operating in the Pharmaceutical Sector. he became the Sales & Marketing Director in 2000 and was CEO from 2002-2009, growing the company organically as well as by joint ventures and acquisitions with operations in the UK as well as overseas. He managed 250 employees and a wide shareholder base of over 700 shareholders. In November 2007 he led a successful trade sale for the company realising an enterprise value of approximately £70million.

For further information, please contact:

Mr. Mahesh Shah, CEO, ProteinLogic Ltd.

Phone: + 44 (0) 845 057 3906

email: mahesh.shah@proteinlogic.com or Claire Sefton, Investor Relations, ProteinLOgic Ltd.@Phone: +4407585958576

Copyright ProteinLogic Ltd March 2010